Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT02224716
Other study ID # FIS-ANT-2014-01
Secondary ID
Status Recruiting
Phase N/A
First received August 22, 2014
Last updated June 11, 2015
Start date July 2014
Est. completion date December 2015

Study information

Verified date June 2015
Source Andalusian Initiative for Advanced Therapies - Fundación Pública Andaluza Progreso y Salud
Contact Pilar Retamar Gentil
Phone 0034 955 04 04 50
Email gestionensayosclinicos.fps@juntadeandalucia.es
Is FDA regulated No
Health authority Spain: Spanish Agency of Medicines
Study type Observational

Clinical Trial Summary

The purpose of this study is to evaluate the impact of a structured package (bundle) in reducing the use of antimicrobials and hospital stay of patients with community-acquired pneumonia (CAP), and no increase in mortality of these patients in different hospitals.


Recruitment information / eligibility

Status Recruiting
Enrollment 968
Est. completion date December 2015
Est. primary completion date December 2015
Accepts healthy volunteers No
Gender Both
Age group 18 Years and older
Eligibility Inclusion Criteria:

- Diagnosis of CAP at hospital admission .

- Age: 18 years or more.

Exclusion Criteria:

- Patients with nosocomial pneumonia or criteria related to health care.

- Patients with severe immunosuppression (HIV infection with <200 CD4+ lymphocytes / mm3), neutropenia (<500 neutrophils / mm3).

- Patient treated with immunosuppressive drugs.

Study Design

Observational Model: Cohort


Related Conditions & MeSH terms


Locations

Country Name City State
Spain Fundación Pública Progreso y Salud Sevilla

Sponsors (1)

Lead Sponsor Collaborator
Fundación Pública Andaluza Progreso y Salud

Country where clinical trial is conducted

Spain, 

Outcome

Type Measure Description Time frame Safety issue
Primary Antimicrobial use in patients hospitalized for CAP. It is measured in defined daily doses (DDD) per 100 hospital stay of patients hospitalized with CAP. twelve months No
Primary Mortality rate to 30 days Number of death of patients hospitalized with CAP, stratified by CURB-65 score. twelve months Yes
Secondary CAP severity CURB-65 or PSI registered. Implementation of quality indicators in the management of CAP. They are expressed as dichotomous variables (yes / no):
Numbers of doctors who register on the clinical history the evaluation of CAP severity by CURB-65 or PSI at hospitalization.
twelve months No
Secondary Microbiological samples at admission. Implementation of quality indicators in the management of CAP. They are expressed as dichotomous variables (yes / no):
Numbers of doctors who taking all microbiological samples recommended in the guideline in the first 6 hours of patient admission.
twelve months No
Secondary Appropriate supportive treatment Implementation of quality indicators in the management of CAP. They are expressed as dichotomous variables (yes / no):
Number of doctors who take supportive treatment according to guideline during the hospitalization.
Twelve months No
Secondary Empirical treatment Implementation of quality indicators in the management of CAP. They are expressed as dichotomous variables (yes / no):
Number of doctors who prescribed empirical treatment according to the guideline at admission.
Twelve months No
Secondary Appropriate sequential therapy. Implementation of quality indicators in the management of CAP. They are expressed as dichotomous variables (yes / no):
Number of doctors who switch to oral therapy according to guideline.
Twelve months No
Secondary Specific antimicrobial treatment Implementation of quality indicators in the management of CAP. They are expressed as dichotomous variables (yes / no):
Number of doctors who prescribed the specific antimicrobial treatment defined in the guideline
Twelve months No
Secondary Total duration of antibiotic therapy. Implementation of quality indicators in the management of CAP. They are expressed as dichotomous variables (yes / no):
Number of doctors who prescribe an antimicrobial treatment during 7 days or less, or 5 days or less after clinical improvement.
Twelve months No
See also
  Status Clinical Trial Phase
Completed NCT02559310 - Study to Compare Lefamulin to Moxifloxacin (With or Without Linezolid) for the Treatment of Adults With Pneumonia Phase 3
Completed NCT01530763 - Safety and Efficacy Study of Ceftaroline Versus a Comparator in Pediatric Subjects With Community Acquired Bacterial Pneumonia (CABP) Phase 2/Phase 3
Completed NCT02517489 - Community-Acquired Pneumonia : Evaluation of Corticosteroids Phase 3
Completed NCT02454114 - HOME FIRST Pilot: a Study of Early Supported Discharge in Patients With Lower Respiratory Tract Infections N/A
Not yet recruiting NCT01937832 - A Phase III Study of Faropenem in the Treatment of Adult Community-acquired Bacterial Pneumonia Phase 3
Completed NCT00653172 - Comparative Study of NXL103 Versus Comparator in Adults With Community Acquired Pneumonia Phase 2
Recruiting NCT02139163 - Epidemiological Study on Community Acquired Pneumonia
Completed NCT03411824 - Lung Ultrasound for Community-acquired Pneumonia Diagnosis in Emergency Medicine
Recruiting NCT06210282 - The Effect of Focused Lung Ultrasonography on Antibiotic Prescribing in General Practice N/A
Withdrawn NCT02269644 - A P3 Comparator Trial in Community Acquired Bacterial Pneumonia Phase 3
Recruiting NCT01963442 - Short Duration Treatment of Non-severe Community Acquired Pneumonia Phase 2
Terminated NCT00887276 - Study to Proof the Clinical and Bacteriological Non-inferiority of Ampicillin/Amoxicillin Versus Moxifloxacin in Hospitalized Patients With Non-severe Community-acquired Pneumonia Phase 4
Not yet recruiting NCT00390819 - Epidemiology of Community Acquired Pneumonia in North Israel N/A
Completed NCT00079885 - Study Evaluating Tigecycline vs Levofloxacin in Hospitalized With Community-Acquired Pneumonia Phase 3
Not yet recruiting NCT04158310 - Evaluation the Clinical Value of Xiyanping Injection in the Treatment of Community-acquired Pneumonia in Children
Recruiting NCT02552342 - Corticosteroid Therapy for Severe Community-Acquired Pneumonia Phase 4
Completed NCT02922387 - Smoking Cessation Intervention in Respiratory Inpatients Phase 4
Completed NCT00467701 - Community Acquired Pneumonia in Telemark and Ostfold N/A
Completed NCT04198571 - Retrospective Chart Review Study to Assess Characteristics, Treatment Outcomes and Resource Use of Adults Hospitalized for CAP and CSSTi Treated With Zinforo in Multiple Countries
Completed NCT02107001 - Lung Ultrasound in Pleuritic Chest Pain N/A